UBS cuts target for Sabra Health Care REIT stock to USD 20.00

Published on 10/17/2026 at 22:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 24.70 percent in second-quarter 2026. Sabra Health Care REIT stock costs USD 19.34 on October 16, 2026, up 0.26 percent on Nasdaq.

Analyst valuation and trading dates

On October 13, 2026, UBS lowered its Sabra target from USD 21.00 to USD 20.00.
For the second quarter of 2026, revenue rose 24.70 percent to USD 230.11 million.
Sabra Health Care REIT stock last stood at USD 19.34 on October 16, 2026 at 4:00 p.m. ET, up 0.26 percent on Nasdaq versus the prior close.
TradingView lists November 9, 2026 as the next earnings date.

SBRA, US78573L1061, Illustration mit AI erstellt.

UBS analyst Michael Goldsmith lowered the price target for Sabra Health Care REIT from USD 21.00 to USD 20.00 on October 13, 2026, while keeping a Neutral rating, according to Markets Insider. The target stood 3.41 percent above the USD 19.34 Nasdaq price. Sabra Health Care REIT last stood at USD 19.34 on October 16, 2026 at 4:00 p.m. ET, up 0.26 percent versus the prior Nasdaq close.

Revenue exceeded expectations

Sabra reported revenue of USD 230.11 million in the second quarter of 2026, up 24.70 percent from the year-earlier period. The figure exceeded the USD 219.39 million consensus estimate, while diluted earnings per share were negative USD 0.10 against consensus of USD 0.17, according to MarketBeat. The revenue comparison gives the stock a stronger operating reference than the quarterly earnings-per-share shortfall alone.

Stock remains below yearly high

The Nasdaq price traded between USD 19.19 and USD 19.54 on October 16, 2026. Its 52-week range was USD 17.17 to USD 22.77, leaving the stock 12.64 percent above the low and 15.06 percent below the high. Volume reached 1,716,648 shares against an average of 2,545,854 shares.

Valuation and November date

Sabra had a market capitalization of USD 4.9 billion, a price-to-earnings ratio of 73.70 and a trailing dividend yield of 6.00 percent as of October 17, 2026. TradingView lists November 9, 2026 as the next earnings date. The company operates as a healthcare real estate investment trust focused on skilled nursing, senior housing and behavioral health facilities.

Comparison with peers

Sabra Health Care REIT (Nasdaq, USD): plus 0.26 percent, price-to-earnings ratio 73.70, market capitalization USD 4.9 billion.

Healthcare Realty Trust (NYSE, USD): plus 0.69 percent, price-to-earnings ratio minus 66.64, market capitalization USD 6.1 billion.

Ventas (NYSE, USD): plus 1.18 percent, price-to-earnings ratio 159.00, market capitalization USD 44.0 billion.

Price remains the key market marker

Sabra combines a 6.00 percent trailing dividend yield with a 73.70 price-to-earnings ratio and a recent quarterly revenue increase of 24.70 percent. The next scheduled earnings date on November 9, 2026 will provide the next formal checkpoint for those figures.

The last Nasdaq price was USD 19.34 on October 16, 2026 at 4:00 p.m. ET, up 0.26 percent versus the prior Nasdaq close.